Sunday, 2 November 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 02 November 2025
News

Shake-up in top PBS earners list

Posted 31 October 2025 AM

There has been a shake-up in the list of exclusive brands with the highest PBS reimbursements this quarter as two huge medicines faced biosimilar competition for the first time.

Johnson & Johnson's Stelara was joined on the PBS by Celltrion's SteQeyma in August. Due to the way the PBS reports reimbursements the two cannot be separated, but combined they earned $93.9 million in pre-rebate R/PBS reimbursements for the third quarter of 2025, a 21.7 per cent fall compared to the same period in 2024, and 35.1 per cent less than Stelara earned in the prior quarter.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (3)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.